Core Insights - Medtronic's spinoff MiniMed began trading on Nasdaq in early March, with an expected earnings decrease of about 4 cents per share due to the timing of the IPO [3][4] - The company anticipates a dilution of one to two cents per month until the split, but expects the diabetes spinoff to be accretive to its earnings [4] - Medtronic revised its earnings forecast for fiscal year 2026, now expecting adjusted earnings per share of $5.50 to $5.54, a decrease of 12 cents from previous forecasts [8] Financial Impact - Medtronic expects an earnings hit of about 8 cents per share related to the MiniMed Flex insulin pump, with Blackstone receiving royalty payments or minimum payments due to its funding role [5] - A one-time charge of $157 million is expected in MiniMed's fiscal fourth quarter related to future payments to Blackstone, impacting Medtronic due to its 90% ownership stake in the spinoff [8] Regulatory Developments - The FDA clearance for MiniMed's insulin pump was announced on March 18, earlier than anticipated, which may positively influence market perception [6]